MultivisionDx

MultivisionDx, based in Finland, specializes in AI-driven decision-support tools for personalized cancer diagnosis and treatment selection, enhancing clinician capabilities through innovative spatial biology diagnostics. Founded in 2025 and headquartered in Helsinki, Finland, MultivisionDx focuses on developing advanced diagnostic tools for oncology. The company aims to transform cancer treatment through their AI-powered platform. In December 2025, MultivisionDx successfully raised EUR 1 million in pre-seed funding, led by Antler, with participation from Helsinki University Funds and Kaikarhenni Oy.

The founder's history is not specified. MultivisionDx specializes in AI-powered decision-support tools designed for personalized diagnosis and treatment selection in solid cancers. The company's core offering is a spatial biology diagnostics platform that leverages advanced computer vision technology to integrate biological and spatial features of tumors and their microenvironments. This technology generates patient-specific tumor profiles, enabling clinicians to evaluate tumor aggressiveness and customize treatment strategies for individual patients effectively.

By utilizing these tools, healthcare professionals aim to eliminate the trial-and-error approach often associated with cancer treatment, ultimately improving patient outcomes. The products are primarily aimed at oncologists and healthcare institutions involved in cancer treatment, with applications in markets across Europe and North America. Revenue generation for MultivisionDx is anticipated through B2B transactions with healthcare providers and research institutions, focusing on partnership models rather than direct sales to consumers. The company primarily operates under a subscription-based pricing structure, where clients pay for access to its diagnostic tools and ongoing support services.

Revenue streams are expected to derive from partnerships with hospitals and cancer treatment centers that utilize the company's platform to enhance their diagnostic capabilities. These collaborations may also include revenue sharing agreements based on the successful application of the technology in clinical settings. MultivisionDx's flagship products, including its biomarker-discovery platform and composite biomarker for head-and-neck cancer, are expected to play significant roles in these transactions. In December 2025, MultivisionDx raised EUR 1 million in pre-seed funding, which will be utilized to develop tests, validate them, form international partnerships, and access additional public funding for growth.

The company plans to introduce new diagnostic tests that are currently under development, intending to enhance their platform's capabilities. Additionally, MultivisionDx is targeting expansion into new markets in North America and Europe by 2026, aiming to broaden their reach and impact in the oncology sector.